SCYNEXIS Reports First Quarter 2018 Financial Results and Provides Company Update

May 8, 2018

SCYNEXIS's Oral SCY-078 Receives FDA QIDP and Fast Track Designations for the Treatment of VVC and Prevention of Recurrent VVC

May 1, 2018

SCYNEXIS Data Presentations at ECCMID 2018 Show SCY-078 Potent and Synergistic Antifungal Activity Against Aspergillus and Pneumocystis

Apr 23, 2018

SCYNEXIS to Present SCY-078 Data at the 28th European Congress of Clinical Microbiology and Infectious Disease (ECCMID)

Apr 10, 2018

SCYNEXIS to Present at the 17th Annual Needham Healthcare Conference

Mar 21, 2018

SCYNEXIS Presents Data at Superbugs and Superdrugs 2018

Mar 20, 2018

SCYNEXIS Reports Full Year 2017 Financial Results and Provides Company Update

Mar 13, 2018

SCYNEXIS to Present at the 30th Annual ROTH Conference

Mar 7, 2018

SCYNEXIS Announces Pricing of $30.0 Million Public Offering of Common Stock and Warrants

Mar 6, 2018

SCYNEXIS Announces Launch of Public Offering of Common Stock and Warrants

Mar 5, 2018